Welcome to AMRlytics. By accessing or using this platform — including the public website, dashboard, and any beta or pilot features — you agree to these Terms of Use. Please read them carefully.
01What AMRlytics Is
AMRlytics is an early-stage research and surveillance intelligence platform designed for microbiologists, public health researchers, clinicians, pharmacists, and pharma R&D professionals.
The platform aggregates publicly available antimicrobial resistance (AMR) data from sources including WHO GLASS and ECDC EARS-Net, and provides interactive analysis, forecasting, and benchmarking tools.
AMRlytics is currently in beta. Features, data coverage, and methodology may change as the platform evolves.
02Not Medical Advice
AMRlytics is not a clinical decision support system and does not provide medical advice.
Resistance percentages, risk classifications, alerts, and forecasts shown on this platform are population-level surveillance signals — not prescribing recommendations.
Treatment decisions for individual patients must always rely on local antibiograms, susceptibility testing, clinical judgement, current treatment guidelines (e.g., IDSA, EUCAST, national stewardship protocols), and patient-specific factors.
By using AMRlytics, you acknowledge that you will not use the platform as the sole basis for any clinical, diagnostic, or treatment decision.
03Acceptable Use
You agree to use AMRlytics for lawful purposes only. You may:
- Use the platform for research, surveillance review, education, public health work, and stewardship planning
- Cite AMRlytics in academic papers, presentations, and reports with appropriate attribution (see Section 6)
- Share screenshots and visualizations with attribution
You may not:
- Use automated tools, scrapers, or bots to extract data from the platform
- Reverse engineer, decompile, or attempt to bypass any access controls
- Republish AMRlytics content as your own without attribution
- Use AMRlytics in any way that could mislead users into believing it provides medical or prescribing advice
- Resell, redistribute, or commercialize AMRlytics content without explicit written permission
04Pilot Access
Pilot access to AMRlytics is currently provided free of charge to selected researchers, clinicians, and public health professionals.
Pilot users may:
- Receive access credentials by email after their request is reviewed
- Be invited to provide feedback that may influence future development
- Have access modified, suspended, or revoked at any time without notice
Sharing pilot access credentials with unauthorized third parties is not permitted.
05Data Sources and Attribution
AMRlytics integrates publicly available data from international surveillance networks. We acknowledge and credit the following sources:
- WHO GLASS — Global Antimicrobial Resistance and Use Surveillance System (World Health Organization)
- ECDC EARS-Net — European Antimicrobial Resistance Surveillance Network (European Centre for Disease Prevention and Control)
- Additional regional and national sources as integrated
The original data remains the property of its respective source organization. AMRlytics provides analytical interpretation, normalization, and visualization layers on top of these public datasets.
06Citation
If you reference AMRlytics in academic work, publications, presentations, or policy documents, please cite as:
amrlytics.ai. Data: WHO GLASS and ECDC EARS-Net.
Accessed [date].
A formal methods preprint describing AMRlytics is in preparation and will be available on medRxiv. Once published, the preprint should be cited in academic work.
07Intellectual Property
The AMRlytics name, logo, design, dashboard interface, methodology, and original visualizations are the intellectual property of AMRlytics.
Source data from WHO, ECDC, and other surveillance networks remains the property of those organizations and is used in accordance with their respective open data terms.
Where the AMRlytics codebase is open-sourced, it is released under the GNU Affero General Public License v3.0 (AGPL-3.0). Any derivative work must comply with the terms of that license.
08No Warranty
AMRlytics is provided "as is" and "as available." We make no warranties, express or implied, regarding:
- The accuracy, completeness, or timeliness of the surveillance data displayed
- The reliability of forecasts, risk classifications, or alerts
- The continuous availability or uptime of the platform
- Fitness for any particular clinical, regulatory, or commercial purpose
While we work to ensure data quality and methodological transparency, AMRlytics is a beta-stage platform and may contain errors. Users are responsible for independently verifying any information they rely upon.
09Limitation of Liability
To the maximum extent permitted by law, AMRlytics and its operators shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising from your use of — or inability to use — the platform.
This includes, but is not limited to, damages arising from clinical decisions, treatment outcomes, regulatory submissions, business decisions, or any reliance placed on AMRlytics output.
10Privacy
Your use of AMRlytics is also governed by our Privacy Policy, which explains what data we collect, how we use it, and your rights under UK GDPR.
11Changes to These Terms
We may update these Terms of Use as AMRlytics evolves. Any changes will be posted on this page with an updated effective date. Continued use of the platform after changes are posted constitutes acceptance of the revised terms.
12Governing Law
These Terms of Use are governed by the laws of the United Kingdom. Any disputes arising from your use of AMRlytics shall be subject to the exclusive jurisdiction of the courts of the United Kingdom.
13Contact
If you have any questions about these Terms of Use, please contact: